Skip to main content

Practice

Secukinumab Effective in Non-Radiographic Axial SpA

Aug 10, 2020

The PREVENT trial was a one year, phase III study that showed significant benefits when secukinumab (SEC) was given to patients with active non‐radiographic axial spondyloarthritis (nr‐axSpA) for 52 weeks.



To be enrolled patients had to have inflammatory low back pain and have either

Read Article

ACR Applauds E/M Coding Changes, Telehealth Expansion in CY 2021 Physician Fee Schedule Proposed Rule

Aug 07, 2020

The American College of Rheumatology (ACR) today applauded the Centers for Medicare and Medicaid Services (CMS) for taking steps to appropriately value cognitive care and expand telehealth access in its CY 2021 Physician Fee Schedule (PFS) Proposed Rule.

Read Article

RheumNow Podcast – Why Do We Love Rheumatology Fellows? (8.7.20)

Aug 06, 2020

Dr. Jack Cush reviews why we all love our rheumatology fellows and our best advice for them stemming from these articles.

Read Article

Long-Term Rituximab in ANCA-Associated Vasculitis

Aug 06, 2020

The Annals of Internal Medicine reports that biannual rituximab infusions over 18 months was effective at maintaining remission in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Read Article

Lovastatin Fails to Lower CRP and Activity in RA

Aug 04, 2020

Ridker and colleagues have shown that statins (3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors) are effective at treating hyperlipidaemia and lowering C-reactive protein levels; Aranaow and colleagues have shown that lovastatin, when given to rheumatoid arthritis (RA)

Read Article
Virtual Video Joint Exam Pearl #5: Its easier to see gouty Tophi and rheumatoid nodules than nail changes of PsA or subtle rashes. For Rashes and oral lesions its BEST to have the patient take multiple pix with the cell phone and send them in by EMR or Email.

Dr. John Cush RheumNow ( View Tweet)

Aug 04, 2020

Fighting Hydroxychloroquine Misinformation

Aug 03, 2020

JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it

Read Article

More Rheumatology Fellow Advice from the Mentors

Aug 03, 2020

If you’re looking for some great advice to consider or rebuke, here is the generous guidance of nearly two dozen leaders in rheumatology who sincerely offer you their wisdom and best wishes.

Read Article

Uric Acid Targeting in Gout Management

Jul 31, 2020

A study from 2 gout clinics implementing different treatment strategies has shown that a treatment strategy that aims to strictly achieve low uric acid (UA) results in a higher a rate of targetd serum UA lowering and less gout flares.



Two gout clinics with 212 newly diagnosed gout

Read Article

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article

Colchicine Benefits COVID-19 Patients

Jul 30, 2020

A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes.

Efficacy and safety must be determined in controlled clinical trials.he outbreak of COVID-19 posed the issue of urgently identifying treatment strategies.

Read Article

Methotrexate Improves Pegloticase Efficacy and Tolerability

Jul 29, 2020

The efficacy of intravenous pegloticase (PEG) therapy in gout can be limited by its toxicity, but when coadministered with weekly methotrexate, higher response rates and less toxicity was observed.



In published gout clinical trials, the PEG responder rate was 42%. Strategies to limit 

Read Article

The Burden of Gout

Jul 28, 2020

Danve and Neogi have an editorial in the current Arthritis & Rheumatology about the burden of gout that affects 41 million adults worldwide, according to the Global Burden of Disease Study 2017 (GBD 2017) also published in the same issue.

This makes gout twice as prevalent as rheumatoid

Read Article

Serial DEXA May Not Be Advisable

Jul 28, 2020

Does repeat bone mineral density (BMD) measurement predict subsequent fracture risk in postmenopausal women? A study published in JAMA suggests that a second BMD done 3 years after the initial DEXA did not further distinguish women who would be at a higher risk for a future hip fracture or

Read Article

SEMIRA Study: Best to Continue Low Dose Steroids in RA

Jul 28, 2020

The SEMIRA trial studied the  tapering vs continuing oral glucocorticoids in rheumatoid arthritis (RA) patients who achieved a low disease activity state (with tocilizumab) were more likely to show safety and better disease control with continuing steroids - even though two-thirds of patients

Read Article

GI Perforations with Tocilizumab Greater than Other Biologics

Jul 27, 2020

A study from a Swedish population shows the real-world risk of gastrointestinal (GI) perforations in rheumatoid arthritis (RA) patients taking biologics finds that the risk was greatest in RA patients taking tocilizumab (TCZ), compared with RA patient taking tumour necrosis factor inhibitors (

Read Article

ACR Advice on Reopening Strategies

Jul 24, 2020

The American College of Rheumatology (ACR) has issued a guidance document for rheumatologists and rheumatology health professionals to consider as practices, business and patient care begins to reopen in this next phase of the COVID-19 pandemic. This document discusses local conditions,

Read Article

Low Risk of COVID in Biologic Treated Rheum Patients

Jul 23, 2020

In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population. 



Their study included 295

Read Article

Rapid Loss of SARS-CoV-2 Antibodies in Mild Disease

Jul 23, 2020

According to a small, observational study out of UCLA published as correspondence in the NEJM on July 21, 2020, those with mild COVID-19 symptoms showed an approximate antibody half-life of 73 days.

COVID-19 infection was confirmed by PCR in 30 out of 34 study participants. The remaining four

Read Article

Higher Rates of SARS-CoV-2 Seropositivity in the USA

Jul 22, 2020

The number of reporting cases of COVID-19 infection tends to underestimate the true prevalence of infection as only the more severe cases (e.g.,acute respiratory syndrome) get tested or go to the hospital. JAMA Internal Medicine reports that a cross-sectional seroprevalence study from the U.S.

Read Article

For TNF Response in RA, Weight Matters

Jul 22, 2020

Patients with rheumatoid arthritis (RA) who were obese were significantly less likely to remain on treatment with tumor necrosis factor (TNF) inhibitors -- but so were those who were underweight, a large, long-term study determined.

Compared with patients with normal weight, patients in obesity

Read Article

Steroids and Tocilizumab in Cytokine Storm Syndrome

Jul 21, 2020

A recent study from the Netherlands has shown that patients with severe COVID-19-associated cytokine storm syndrome (CSS)  with high dose steroids and tocilizumab had a faster recovery, less need for invasive mechanical ventilation and fewer deaths when compared to CSS patients receiving

Read Article

Risankizumab Outduels Secukinumab in Psoriasis

Jul 20, 2020

The IMMerge trial has demonstrated the superiority of interleukin (IL)‐23 over IL-17A inhibition adults with plaque psoriasis.



This multicenter, phase 3, open‐label study enrolled 327 adult patients with chronic, moderate‐to‐severe plaque psoriasis who were randomised risankizumab (

Read Article

RECOVERY Trial: Dexamethasone in COVID-19

Jul 20, 2020

Inflammatory events following infection with SARS-CoV-2 can often worsen the morbid or mortal outcomes with COVID, yet it has been unclear if glucocorticoids may modulate inflammation-mediated damage and lung injury.  The RECOVERY trial reports that dexamethasone (DEX) use lowered 28-day

Read Article

Characteristics Underlying Mortal COVID-19 Outcomes

Jul 17, 2020

From January 1, 2020–May 18, 2020, approximately 1.3 million cases of coronavirus disease 2019 (COVID-19) and 83,000 COVID-19–associated deaths were reported in the United States. MMWR reports that COVID-19 mortality is higher in persons with underlying medical conditions and in those aged ≥

Read Article
×